Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | COMT | P21964 | 1/20 | 0.50 |
| ▸ | NFE2L2 | Q16236 | 7/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | ACLY | P53396 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31634191 | 1.00 | COMT (0.50) | COMTNFE2L2KDM4EGAAMAPT | |
| SCHEMBL31634218 | 0.80 | NFE2L2 (0.46) | NFE2L2KDM4EGAAMAPTAPOBEC3G | |
| SCHEMBL925929 | 0.80 | NFE2L2 (0.46) | NFE2L2KDM4EGAAMAPTAPOBEC3G | |
| SCHEMBL3704196 | 0.80 | COMT (0.47) | COMTNFE2L2LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL19434109 | 0.80 | COMT (0.53) | COMTKDM4EGAAMAPTAPOBEC3G | |
| SCHEMBL28274692 | 0.79 | TSHR (0.50) | NFE2L2KDM4EMAPTNPSR1LMNA | |
| SCHEMBL9488733 | 0.79 | ALDH1A1 (0.63) | NFE2L2KDM4EMAPTLMNASMN1; SMN2 | |
| SCHEMBL3698654 | 0.78 | COMT (0.46) | COMTNFE2L2LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL3713453 | 0.78 | COMT (0.46) | COMTNFE2L2LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL3698635 | 0.78 | COMT (0.46) | COMTNFE2L2LMNASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107849027-A | Active 1,2,4 triazole derivatives of harmful organism are killed with sulfur-bearing substituent | 先正达参股股份有限公司 | 2018-03-27 | — | — | CN | disclosed |
| CN-107735396-A | Harmful organism activity Polycyclic derivative is killed with sulfur-bearing substituent | 先正达参股股份有限公司 | 2018-02-23 | — | — | CN | disclosed |
| CN-107207501-A | Pesticidally active polycyclic derivatives with sulfur-containing substituents | 先正达参股股份有限公司 | 2017-09-26 | — | — | CN | disclosed |
| US-9738649-B2 | Tetrahydro-pyrimidoazepines as modulators of TRPV1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2017-08-22 | — | — | US | disclosed |
| CN-107074865-A | The active Polycyclic derivative of harmful organism is killed with sulfur-bearing substituent | 先正达参股股份有限公司 | 2017-08-18 | — | — | CN | disclosed |
| US-20160318942-A1 | TETRAHYDRO-PYRIMIDOAZEPINES AS MODULATORS OF TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-03 | — | — | US | disclosed |
| US-9422293-B2 | Tetrahydro-pyrimidoazepines as modulators of TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2016-08-23 | — | — | US | disclosed |
| US-20140135311-A1 | TETRAHYDRO-PYRIMIDOAZEPINES AS MODULATORS OF TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-15 | — | — | US | disclosed |
| EP-2024368-B1 | 6,7,8,9-TETRAHYDRO-5H-PYRIMIDO[4,5-D]AZEPIN-4-YL]-AMINE DERIVATIVES AS MODULATORS OF TRPV1 FOR THE TREATMENT OF PAIN | JANSSEN PHARMACEUTICA NV (BE) | 2014-04-30 | — | — | EP | disclosed |
| US-8673895-B2 | Tetrahydro-pyrimidoazepines as modulators of TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2014-03-18 | — | — | US | disclosed |
| US-7312330-B2 | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312330-B2 | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312330-B2 | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-20070225275-A1 | Tetrahydro-pyrimidoazepines as modulators of TRPV1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-27 | — | — | US | disclosed |
| WO-2007109355-A2 | 6,7,8, 9 -TETRAHYDRO- 5H- PYRIMIDO [4, 5-D] AZEPIN-4-YL] -AMINE DERIVATIVES AS MODULATORS OF TRPVL FOR THE TREATMENT OF PAIN | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-27 | — | — | WO | disclosed |
| WO-2006118598-A1 | BICYCLOHETEROARYLAMINE COMPOUNDS AS ION CHANNEL LIGANDS AND USES THEREOF | RENOVIS, INC. (US) | 2006-11-09 | — | — | WO | disclosed |
| EP-1697361-A1 | BICYCLOHETEROARYLAMINE COMPOUNDS AS ION CHANNEL LIGANDS AND USES THEREOF | Renovis, Inc. (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20050277643-A1 | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof | EVOTEC AG (DE) | 2005-12-15 | — | — | US | disclosed |
| US-20050215572-A1 | N-(4-tert-Butyl-phenyl)-[7-(3-chloro-pyridin-2-yl)-2-methoxymethyl-5,6,7,8-tetrahydro-pyrido[3,4-d]pyrimidin-4-yl]-amine; antiinflammatory agents treating pain, inflammation, traumatic injury, arthritis, Parkinson's disease, Alzheimer's disease, stroke, asthma, myocardial infarction | EVOTEC AG (DE) | 2005-09-29 | — | — | US | disclosed |
| WO-2005066171-A1 | BICYCLOHETEROARYLAMINE COMPOUNDS AS ION CHANNEL LIGANDS AND USES THEREOF | RENOVIS, INC. (US) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318942-A1 | TETRAHYDRO-PYRIMIDOAZEPINES AS MODULATORS OF TRPV1 | TRPV1, TRPA1, TRPV2 | COMT 2010/4885NFE2L2 2782/4885KDM4E 3145/4885 |
| US-20140135311-A1 | TETRAHYDRO-PYRIMIDOAZEPINES AS MODULATORS OF TRPV1 | TRPV1, TRPA1, TRPV2 | COMT 2010/4885NFE2L2 2782/4885KDM4E 3145/4885 |
| US-20070225275-A1 | Tetrahydro-pyrimidoazepines as modulators of TRPV1 | TRPV1, TRPA1, TRPV2 | COMT 1905/4885NFE2L2 2666/4885KDM4E 3173/4885 |
| US-20050215572-A1 | N-(4-tert-Butyl-phenyl)-[7-(3-chloro-pyridin-2-yl)-2-methoxymethyl-5,6,7,8-tetrahydro-pyrido[3,4-d]pyrimidin-4-yl]-amine; antiinflammatory agents treating pain, inflammation, traumatic injury, arthritis, Parkinson's disease, Alzheimer's disease, stroke, asthma, myocardial infarction | PARK7, PTGIS, PTGES | COMT 311/4885NFE2L2 292/4885KDM4E 2905/4885 |
| US-20050277643-A1 | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof | TRPV1, TRPV3, TRPA1 | COMT 2408/4885NFE2L2 1017/4885KDM4E 3991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.